ChAd3-EBO Z

BIOLOGICAL3 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford

Conditions

Ebola VirusEbola Virus Disease

Phase 1

A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z

TerminatedNCT02451891

University of OxfordEbola Virus Disease

Start: 2015-05-06End: 2017-08-22Updated: 2025-12-18

Evaluation of a New Ebola Vaccine Using a Short-interval Prime-boost Vaccination

CompletedNCT02485912

University of OxfordEbola Virus Disease

Start: 2015-07-31End: 2016-01-31Updated: 2019-02-06

Phase 2

Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)

CompletedNCT02344407

National Institute of Allergy and Infectious Diseases (NIAID)Ebola Virus

Start: 2015-01-20End: 2020-11-01Updated: 2021-04-08

Related Papers

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine (ERVEBO®) in African clinical trial participants by age, sex, and baseline GP-ELISA titer: A post hoc analysis of three Phase 2/3 trials.

2022-10-0516 citations

Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus - Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis.

2020-06-0111 citations

Safety and Immunogenicity of a Heterologous Prime-Boost Ebola Virus Vaccine Regimen in Healthy Adults in the United Kingdom and Senegal

The Journal of Infectious Diseases2018-11-0482 citations

Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia

New England Journal of Medicine2017-10-11249 citations

Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic.

2017-06-2135 citations

Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial.

2015-11-04162 citations